Cover Innovationsreport 2015Cover Innovationsreport 2015
Traffic Light Rating and Prescription of Newly Registered Drugs.

This is the third publication of the Innovation Report. Edited by Gerd Glaeske, Petra Thürmann and Wolf-Dieter Ludwig, the Innovation Report provides the first data on prescriptions of new drugs – which distinguishes it from all other reports on pharmaceutical products. These drugs, which have undergone the AMNOG early evaluation process, are subjected to a review which also includes everyday medical treatment. Both the prescribed amounts and expenditure are considered and set in relation to the benefit of these medicines in their respective indications.

Gerd Glaeske (SOCIUM, University of Bremen), Wolf-Dieter Ludwig (HELIOS-Klinikum Berlin-Buch and Chair of the Drug Commission of the German Medical Association) and Jens Baas (Chair of the Board of the Techniker Krankenkasse health fund) presented the Innovation Report 2015 on September 9th, 2015 in Berlin. The report was drawn up, with the kind support of the Techniker Krankenkasse, by a team of authors comprising Daniela Boeschen, Dörte Fuchs, Dr. Judith Günther and Prof. Dr. Gerd Glaeske from the Health Care Research Division of the Department of Health, Long-Term Care and Pensions at SOCIUM (formerly ZeS), University of Bremen. The report evaluates evidence on and the efficacy of new medicines that came onto the market in 2012 and considers their prescriptions in the years 2012 and 2013 in the light of routine data from the Techniker Krankenkasse.

Download: Innovationsreport, Long Version, in German

Prof. Dr. Gerd Glaeske (verstorben)

Patient oriented outcome research - yesterday, today, tomorrow.

Health services research has achieved a lot in the meantime - but is it enough? The Advisory Council on Health claimed in its report of 2000/2001 an expansion of outcome research and an increased use of administrative data. This includes primarily the presentation of rational and quality-oriented patient care through methodologically adequate studies, the revealing of overuse, underuse and misuse of care and an evaluation of health policy-induced changes in our health care system. These aspects still determine future challenges for health services research on a medical, political and economic level:

  • more comprehensive evaluation concepts of therapeutic measures in favor of patients and from the perspective of patients on the basis of adequate funding;

  • development of new concepts to improve care structures and processes;

  • improved transfer of research results for the public and increased consideration of the findings in politics.

The congress focuses on outcome research by taking into account already achieved results and future requirements for improvement opportunities regarding the quality of care.

Dr. Christoph Straub
CEO of Barmer GEK

Prof. Dr. Gerd Glaeske (verstorben)

Bestandsmarktreport 2014Bestandsmarktreport 2014
The Centre for Social Policy Research (ZeS) at the University of Bremen continues the cost-benefit assessment of drugs with existing admission to the pharmaceuticals market.

Since 2011, the Pharmaceuticals Market Reorganization Act (AMNOG) stipulates an early assessment for newly approved drugs if they are to be prescribed within the statutory health insurance (SHI). This cost-benefit assessment has consequences for the drug prices in the SHI Pharmaceuticals Market. The original intention was to subject important and often prescribed pharmaceuticals of the existing drug market to an AMNOG efficiency rating as well. This law, however, was changed on April 1, 2014, the examination of the already registered drugs was abolished. Medicines, which, compared to proven and affordable treatment alternatives, do not have recognized additional benefits, continue to cause unnecessary costs for the SHI in the billions.

The Centre for Social Policy Research (ZeS) has continued the review process for certain drug groups with the kind support of the TK, a German health insurance fund. The German Federal Joint Committee, the G-BA, had commenced this process before the abolition of the law with a few medicines of the existing pharmaceuticals market.
The market development of selected drug groups was illustrated by routine data of the TK health insurance fund. The focuses of the review are new oral anticoagulants, newer antidiabetic drugs (GLP-1 agonists and DPP-4 inhibitors) and drugs for the treatment of rheumatoid arthritis.

The evaluated 17 drugs were assessed on the basis of a literature review in relation to their patient-oriented additional advantage, compared to established drug therapy options. None of the drugs was evaluated positively in the overall assessment. For example, none of the six studied antidiabetic obtained an additional asset. Of the products still in the market (two antidiabetic agents were withdrawn from the market because the manufacturers could not implement their price expectations) only two (still more expensive than comparative therapies or agents of first choice) were cheaper in relation to drugs from the same drug class.

Overall, our results highlighted the need for the AMNOG rating of the existing pharmaceuticals market to improve the efficiency of the drug supply. The results of this report will therefore be placed at the disposal of prescribing physicians.

Download: Bestandsmarktreport 2014, in German

Prof. Dr. Gerd Glaeske (verstorben)

Dipl.-Soz. Friederike Höfel

from left to right: M. Schrappe, W.-D. Ludwig, G. Glaeske, S. Kapferer (Source: BMG)from left to right: M. Schrappe, W.-D. Ludwig, G. Glaeske, S. Kapferer (Source: BMG)
The Report was realized under the direction of Professor Gerd Glaeske and was handed over to Stefan Kapferer, state secretary of the Federal Ministry of Health, 11.1.2011 in Berlin

The professors Klaus Höffken, Wolf-Dieter Ludwig, Matthias Schrappe, Lothar Weißbach and Eberhard Wille, as well as the research fellows Maike Rehrmann and Friederike Höfel were involved as experts.

The Onkology-Report was commissioned by the Federal Ministry of Health in 2009 within the National Cancerplan. Besides an extended review of the developements in oncological pharmacotherapy regarding medical and economic aspects, the pharmaceutical and social law, the authors suggest strategies to secure an efficient and evidence-based pharmacological treatment. Furthermore, concepts were introduced for differentiated financing of the expensive oncological drugs. In addition to research on the benefit of these drugs in health care reality, the patient orientation was strengthened by presenting strategies for the provision of neutral information.

The report provides an important basis for discussions and the work of the National Cancerplan.

Download (in German):
Press release from 11th January 2011, Bundesministerium für Gesundheit

Expertise (in German):
Glaeske, Gerd; Rehrmann, Maike; Höffken, Klaus; Ludwig, Wolf-Dieter; Schrappe, Matthias; Weißbach, Lothar; Wille, Eberhard, 2010: Sicherstellung einer effizienten Arzneimittelversorgung in der Onkologie, on behalf of: Bundesministerium für Gesundheit, Berlin, 11.01.2011

Prof. Dr. Gerd Glaeske (verstorben)

Dipl.-Soz. Friederike Höfel